Contact Us

MEETING NEWS

Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC

Feb 13, 2025

HONG KONG,Feb. 13,2025--Akeso,Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized,double-blind,mult

Hankyung.com introduces: CODIT Launches AI-Powered English Policy Dashboard to Help Global Companies Track Korean Regulatory Changes

Feb 13, 2025

New platform provides real-time updates on Korean legislation and policy shifts for government affairs and legal teams

Line Inspectors: Treading the Mountain, Crossing the Snow To Guarantee the Power Supply

Feb 11, 2025

SHIHEZI,China,Feb. 10,2025-- On February 4th,the seventh day of the first lunar month,the General Mountain inShihezi City was enveloped in boundless whiteness. Early in the morning,Zhang Lin and L&uum

CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

Feb 11, 2025

SUZHOU,China,Feb. 10,2025-- CStone Pharmaceuticals ("CStone",HKEX: 2616),an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies,today

Toys to Promote Well-being for the Elderly Designed by Chula Lecturers

Feb 11, 2025

BANGKOK,Feb. 10,2025-- AChulalecturer,Associate Professor Pornthep Lertthewasiri,has developed innovative "toys and home decorations for the elderly" to enhance their physical and mental wel

WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year

Feb 11, 2025

Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO,driving innovation for a healthier future

1 ... 95 96 97 98 99 100 101 ... 339